This randomized controlled trial study aims at investigating the efficacy and safety of topical antioxidants in treatment of a cohort of non-elderly volunteers with photoaged skin.

Start Date01 Apr 2021

Sponsor / Collaborator

Sohag University

TCTR20211122002 / RecruitingPhase 4IIT

An open-label, pilot study evaluating the efficacy of a lip balm containing panthenol and bisabolol as a monotherapy for the treatment of mild to moderate cheilitis

Start Date20 Oct 2020

Sponsor / Collaborator-

100 Clinical Results associated with Dexpanthenol

100 Translational Medicine associated with Dexpanthenol

100 Patents (Medical) associated with Dexpanthenol

1,013

Literatures (Medical) associated with Dexpanthenol

01 Mar 2024·Current drug research reviews

Biological Importance, Pharmacological Activities, and Nutraceutical Potential of Capsanthin: A Review of Capsicum Plant Capsaicinoids

Article

Author: Patel, Kanika ; Patel, Dinesh Kumar

Background::

Carotenoids are natural hydrocarbons that play an important role in photomorphogenesis, photosynthesis, photoprotection, development, and defense mechanism of plants. Carotenoids have good anti-oxidants and provitamin A contents with their additional colorant nature, which are indispensable to plants and human diets. Capsicum species are well known for their culinary uses worldwide; they are not only cultivated as vegetables but used in numerous medicinal preparations as well due to their medicinal aspects. This article aims to collect data on the beneficial aspects of capsaicinoids with a major emphasis on capsanthin.

Methods::

In order to investigate the biological potential and therapeutic benefit of capsanthin in medicine, in the present work, scientific research data on capsanthin were collected from different literature sources and analyzed. The biological potential of Capsicum annuum in medicine was also investigated through literature data analysis of different scientific research work. Scientific data on capsanthin were collected from Google, Google Scholar, PubMed, Science Direct, and Scopus using the term capsanthin and capsicum in the present work. Detailed pharmacological activities of capsanthin were presented and discussed in the present work through scientific data analysis of research work. Analytical techniques for the separation, isolation, and identification of capsanthin were taken into consideration in this work.

Results::

Scientific data analysis revealed the biological importance and therapeutic benefit of capsanthin and capsicum in medicine. Capsicum annuum is a member of the Solanaceae family, which is one of the most cultivated spices worldwide. Capsaicinoids are one of the main classes of phytochemicals found in chili peppers, i.e., Capsicum annuum, and are mainly responsible for the pungent and spicy flavor of chili peppers. Capsanthin is a crystalline red color pigment found as the main component of Capsicum annuum fruits during ripening. Capsanthin is also found in Lilium, Aesculus, Berberis, and Asparagus officinalis. Chemically, capsanthin contains a cyclopentane ring, 11 conjugated double bonds, and a conjugated keto group. Capsanthin is a powerful antioxidant, exhibits anti-tumor activities, attenuates obesity-induced inflammation, and raises plasma HDL cholesterol levels. Scientific studies have proven the pharmacological benefits of capsanthin in medicine as it is helpful in pain relief, cardioprotection, weight loss, and body temperature regulation. Moreover, it also has anti-inflammatory, anticancer, antioxidant, and antimicrobial activities. In the literature database, numerous extraction and isolation techniques have been documented for capsanthin. In addition, the analytical techniques and other bioanalytical tools for the isolation and identification of capsanthin were also discussed in the present article.

Conclusion::

Medicinal importance and pharmacological activities of capsanthin were reviewed and discussed in this paper. This review aimed to highlight the literature on capsanthin in drug discoveries with their analytical development.

01 Feb 2024·Naunyn-Schmiedeberg's archives of pharmacology

Dexpanthenol protects against nicotine-induced kidney injury by reducing oxidative stress and apoptosis through activation of the AKT/Nrf2/HO-1 pathway

Article

Author: Taşlıdere, Elif ; Gürel, Elif ; Aslan, Meral ; Üremiş, Muhammed Mehdi

Dexpanthenol (DEX), a subtype of vitamin B5, plays an important role in anabolic reactions, cellular energy and regeneration in the body. Nicotine has been shown to induce kidney damage through the mechanisms of oxidative stress and apoptosis. The purpose of this study was to investigate the potential protective effects of DEX against nicotine-induced kidney damage through modulation of the AKT/Nrf2/HO-1 signaling pathway. Male rats were intraperitoneally administered with 0.5 mg/kg/day nicotine and/or 500 mg/kg/day DEX for 8 weeks. Following administration, renal function tests were conducted on serum samples, and histopathological examinations and analysis of oxidative stress markers and antioxidant enzymes were performed on tissue samples. Protein levels of Akt, Nrf-2, HO-1, Bcl-xL, and Caspase-9 were also evaluated. Nicotine administration resulted in decreased protein levels of p-Akt, Nrf-2, HO-1, and Bcl-xL and increased Caspase-9 protein levels. In addition, nicotine administration caused an increase in MDA, TOS, and OSI levels and a decrease in GSH, GSH-Px, GST, CAT, SOD, and TAS levels. Additionally, BUN and Creatinine levels increased after nicotine administration. DEX administration positively regulated these parameters and brought them closer to control levels. Nicotine-induced kidney injury caused apoptosis and oxidative stress through Caspase-9 activation. DEX effectively prevented nicotine-induced kidney damage by increasing intracellular antioxidant levels and regulating apoptosis through Bcl-xL activation. These findings suggest that DEX has potential as a protective agent against nicotine-induced kidney damage.

01 Feb 2024·Contact dermatitis

Cream versus ointment: Randomized single‐blinded study on the adherence to treatment with topical methylprednisolone aceponate

Article

Author: Franke, Lisa ; Tittelbach, Jörg ; Breternitz-Gruhne, Maria ; Schiller, Isabella ; Elsner, Peter ; Gregersen, Deborah Maria ; Bahr, Viola ; Schumacher, Ulrike ; Peckruhn, Melanie

Abstract:

Background:

Overall adherence in the treatment of chronic dermatoses is poor. Textbooks state an adherence dependence on galenics.

Trial Design:

Prospective, randomized, parallel‐grouped, single‐blinded (investigator), monocentric clinical trial (phase IV) on the adherence to treatment of chronic mild to moderate hand eczema with topical methylprednisolone aceponate (MPA, Advantan®) in different vehicles.

Objectives and Endpoints:

Primary objective was the assessment of the adherence depending on vehicle type in patients with chronic hand eczema. Secondary objective was improvement after a 4‐week treatment period. Primary Endpoint Adherence is defined as the percentage of patients applying at least aimed daily dose. Prescribed daily dose was defined as the planned number of applications per day (1) * surface (measured) * aimed amount per application (mg/cm2). Truly applicated daily dose was evaluated as individual mean amount per dose * individual mean number of applications per day.Adherence was assumed, iftruly applicated daily dose is at least 75% of the prescribed daily dose andthe individual mean number of applications per day is at least 0.85.Secondary Endpoint Efficacy was measured by improvement of Hand Eczema Severity Index (HECSI) and Investigator's Global Assessment (IGA) after a 4‐week treatment period and in addition to Quality of Life in Hand Eczema Questionnaire (QOLHEQ) and Visual Analogue Scale (VAS) to assess pruritus.

Methods:

Number of participants randomized to each group 40, 80 total. Group 1 MPA‐C: Methylprednisolone aceponate 0.1% cream and barrier repair emollient (Bepanthen® Sensiderm). Group 2 MPA‐FO: Methylprednisolone aceponate 0.1% fatty ointment and barrier repair emollient (Bepanthen® Sensiderm). Adherence to treatment was compared via Fisher's exact test.

Results:

Of the patients, 48% were adherent according to our definition. There was no significant difference between MPA‐C (42.1%) and MPA‐FO (54.1%; p = 0.36; group difference—12.0%, 95% CI—34.3%–11.5%). Generalized‐linear‐model‐analysis of adherence to study treatment with factors emollient use, treatment, time and treatment‐time interaction showed a parallel between adherence and amount of emollient use (odds ratio 1.74, p = 0.0038; 95% CI—1.22–2.52). Improvement of hand eczema was seen according to clinical scores without remarkable differences between the groups.

Conclusions:

No dependence of adherence on galenics of topical treatment of chronic hand eczema could be proved. Patients who use more emollient tend to be more adherent to the topical treatment.

News (Medical) associated with Dexpanthenol

04 Apr 2023

·www.drugs.com

AHA News: What's Up With Carrots? Let's Root Out the Truth

TUESDAY, April 4, 2023 (American Heart Association News) -- If you think of carrots as stodgy old tubers, something more fit for rabbits than healthy humans, you're in for a bunch of surprises. Carrots can be a significant source of crucial nutrients, said Sherry Tanumihardjo, professor of nutritional sciences at the University of Wisconsin-Madison. These days, they're popping up in a whole palette of colors. They're also convenient and versatile. "You can just take them out of the ground, wash them and eat them, just like that, or you can peel them and cut them up," she said. "You can slice them and dice them into all kinds of foods." Carrots have been around a long time, probably originating in central Asia, possibly Afghanistan. Researchers say that by the Middle Ages, purple and white varieties were domesticated as far west as England, but the orange carrot didn't become common until the 15th century in Europe. Tanumihardjo has quite a carrot history herself, having studied them since the start of this century and collaborated on work that's helped make a rainbow of varieties widely available. Although carrots carry a range of nutrients, including B vitamins, vitamin K and potassium, much of her carrot enthusiasm comes from her work in vitamin A, which supports the immune system, heart, lungs and perhaps most famously, eye health. "Vitamin A is essential for vision, especially at night," she said, meaning that what your grandmother told you about eating carrots to help you see in the dark has some truth to it. (The idea that carrots can improve eyesight is rooted in British World War II propaganda, but vitamin A deficiency causes hundreds of thousands of cases of night blindness worldwide each year.) Vitamin A comes in two forms. Preformed vitamin A can be found in animal products, such as dairy products and organ meats. Taken in excess, as in supplements, preformed vitamin A can become toxic. The other form, provitamin A, is derived from plant-based chemicals called, conveniently enough, carotenoids. Not all carotenoids can be converted to vitamin A, but orange carrots are full of some that do, such as alpha and beta carotene. "It's a safer way to get vitamin A because your body regulates it," Tanumihardjo said. That is, your body can make more or less, depending on what it needs at the moment. As calculated by the U.S. Department of Agriculture, one regular raw carrot, weighing about 2 ounces (or 60 grams), comes with about 25 calories and would provide nearly 72% of the vitamin A an adult woman's needs, and about 56% of an adult man's daily needs. In the carrot world, colors are trending, and as colors vary, so do nutrients. Purple carrots get their hue from anthocyanins, which have been linked to healthy gut biomes, improved cognition and better heart health. Yellow carrots provide lutein, which helps vision and brain health. And red carrots contain lycopene, which also is found in red tomatoes and watermelon, and which has been linked to lower stroke risk. More varieties may be on the way, Tanumihardjo said. "Right now, we are working on a purple carrot with a red center." Carrots also have heart-healthy fiber. According to the USDA, one regular raw carrot provides 1.7 grams. Federal dietary guidelines say an adult needs 22 to 34 grams a day, depending on age and sex. Tanumihardjo said the nutrients in carrots are available fresh or frozen, raw or cooked. Cooking, she said, breaks down the cell walls releasing compounds that help sweeten carrots a bit. Some studies have shown that cooking actually increases levels of available carotenoids. She did have one carrot caveat, however: If you eat raw carrots without a fat source, you won't see benefits from those carotenoids. "It will just pass right on through the body," she said. "If you eat carrots in a salad and you have salad dressing, then you will absorb more. If you eat carrots in a stew, and you don't overcook them too much, and there's fat in the stew, you will absorb even more." Eating them with a little bit of cheese also would work, she said. The same goes for carrot juice. Juicing breaks cell membranes and helps make carotenoids more accessible, "but you do have to make sure you have a little bit of fat within the same time you're drinking the juice in order to absorb the most nutrients." Although peeling them will remove a little fiber, when it comes to serving carrots, there really isn't a bad way, she said. (Unless, perhaps, you are a rabbit. According to Britain's Royal Society for the Prevention of Cruelty to Animals, wild rabbits don't eat carrots, and they should only be an occasional treat for pets. The whole connection between bunnies and carrots can be traced to the debut of Bugs Bunny in 1940. His carrot crunching was intended as a parody of Clark Gable in the 1934 comedy, "It Happened One Night.") "I do like carrots," Tanumihardjo said. Sometimes she snacks on baby carrots, a peeled and cut version with similar nutritional values. Mostly, she said, she buys longer ones and puts them in soup. "I make a lot of soup." American Heart Association News covers heart and brain health. Not all views expressed in this story reflect the official position of the American Heart Association. Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. By Michael Merschel, American Heart Association News Posted April 2023

AHA

27 Feb 2023

·www.bayer.com

Bayer: Significant growth in sales and earnings

Leverkusen, February 28, 2023 – The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the challenging environment. We were able to deliver, even during these difficult times, and met the upgraded financial targets we set in August,” said Werner Baumann, Chairman of the Board of Management, at the company’s Financial News Conference on Tuesday. The company is active in the right fields, he said. “Health and nutrition are fundamental human needs. Our vision of Health for all, hunger for none is and will remain vitally important, especially in times like these.” Group sales came in at 50.739 billion euros in 2022, up 8.7 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). EBITDA before special items rose by 20.9 percent to 13.513 billion euros, and included a positive currency effect of 429 million euros (2021: negative currency effect of 507 million euros). The EBITDA margin before special items increased to 26.6 percent (2021: 25.4 percent). EBIT amounted to 7.012 billion euros, and was therefore more than twice as high as in the previous year. Net income came in at 4.150 billion euros (2021: 1.000 billion euros), while core earnings per share rose by 22.0 percent to 7.94 euros. Free cash flow more than doubled against the prior year, rising to 3.111 billion euros. Net financial debt amounted to 31.809 billion euros as of December 31, 2022, down 4.0 percent from year-end 2021. Cash inflows from operating activities and the sale of the Environmental Science Professional business were partially offset by cash outflows for dividends and negative currency effects. “These are very good results. Together with the Supervisory Board, we are therefore proposing a dividend of 2.40 euros to the Annual Stockholders’ Meeting. This represents a 20 percent increase compared to the previous year,” said Chief Financial Officer Wolfgang Nickl. With 982.42 million shares entitled to the dividend, the company is therefore set to distribute a total of 2.358 billion euros to stockholders for fiscal 2022 (fiscal 2021: 1.965 billion euros). Crop Science achieves record sales and industry-leading margin Sales in the agricultural business (Crop Science) advanced by 15.6 percent (Fx & portfolio adj.) to a record 25.169 billion euros, with business up in all regions. Growth was strongest at Herbicides (Fx & portfolio adj. 43.9 percent), which saw sales rise in Latin and North America and in Europe/Middle East/Africa in particular thanks to higher prices, as supply for glyphosate-based products was tight. Sales at Corn Seed & Traits rose 8.8 percent (Fx & portfolio adj.) as the division increased its market share. Price increases in all regions more than offset a decrease in acreages in North America and lower license revenues. Sales at Fungicides were up 5.2 percent (Fx & portfolio adj.), with higher prices in the Latin America and Europe/Middle East/Africa regions in particular more than offsetting a decline in volumes in North America. Sales at Soybean Seed & Traits were level with the prior year, with business growing in Latin America but declining in North America due to lower volumes. EBITDA before special items at Crop Science advanced by 46.2 percent to 6.867 billion euros, mainly due to the significant increase in sales. Earnings also benefited from contributions from ongoing efficiency programs and a positive currency effect of 284 million euros (2021: negative currency effect of 387 million euros). By contrast, earnings were mainly diminished by an increase in the cost of goods sold, which was primarily due to high inflation. The EBITDA margin before special items increased by 4.1 percentage points to an industry-leading 27.3 percent. Pharmaceuticals benefits from new products and Eylea™ Sales of prescription medicines (Pharmaceuticals) increased by 1.1 percent (Fx & portfolio adj.) to 19.252 billion euros. Over half a billion euros in sales came from the division’s new products: the cancer drug Nubeqa™ and Kerendia™ for the treatment of chronic kidney disease associated with type 2 diabetes. Sales of Nubeqa™, for instance, almost doubled year on year. Strong growth was also recorded for the ophthalmology drug Eylea™ (Fx & portfolio adj. plus 9.2 percent) and in the radiology business, which includes the Gadovist™ (Fx & portfolio adj. plus 9.0 percent) and Ultravist™ (Fx & portfolio adj. plus 17.5 percent) product lines. This was partially offset by declines due to factors such as additional tender procedures in China, especially for the oral anticoagulant Xarelto™ (Fx & portfolio adj. minus 5.8 percent) and the cancer drug Nexavar™ (Fx & portfolio adj. minus 41.2 percent). Xarelto™ sales were also impacted by price pressure in the United Kingdom and the expiration of the patent in Brazil. EBITDA before special items at Pharmaceuticals rose by 1.6 percent to 5.873 billion euros, benefiting from the increase in sales and, to a lesser extent, from income from the sale of non-core businesses. Earnings were diminished by investments in marketing new products and higher research and development expenses for platform technologies and projects in advanced clinical development. In addition, higher costs due to a sharp increase in procurement prices had a negative effect. There was a positive currency effect of 9 million euros (2021: negative currency effect of 77 million euros). The EBITDA margin before special items declined by 1.0 percentage points to 30.5 percent. Consumer Health grows business in all regions and categories Sales of self-care products (Consumer Health) rose by 8.4 percent (Fx & portfolio adj.) to 6.080 billion euros, with growth in all regions and categories against a strong prior year. The Allergy & Cold business registered the strongest gains, with sales up by a significant 21.5 percent following continuously elevated cold incidence rates and the launch of the Astepro™ antihistamine nasal spray in the United States. The Dermatology category also achieved double-digit percentage growth (Fx & portfolio adj. 10.5 percent), in part due to higher demand for Bepanthen™. After a very strong prior year, the Nutritionals business also registered an increase in sales (Fx & portfolio adj. 1.0 percent). EBITDA before special items at Consumer Health rose by 14.9 percent to 1.367 billion euros following the substantial increase in sales, strong contributions from productivity programs and active price management. The division achieved this growth in a business environment that was impacted by significant inflation-related cost increases while also making large investments in the launch of innovative products, especially for Astepro™. There was a positive currency effect of 85 million euros (2021: negative currency effect of 39 million euros). The EBITDA margin before special items came in at 22.5 percent, matching the prior-year figure. Outlook: Further growth in sales – Earnings below prior year due to inflation and price factors “Following two consecutive years of high single-digit percentage growth rates, we expect our business to remain at a high level and grow by two to three percent in 2023 on a currency- and portfolio-adjusted basis,” said Baumann. The company anticipates lower prices for agricultural herbicides as well as for some of its established pharmaceutical products. Projected sales growth in the other parts of the portfolio and from new products are expected to have a positive impact. As regards earnings in 2023, growth-driven margin contributions and positive effects from ongoing efficiency programs will not be sufficient to offset the anticipated decline in prices as well as high inflation-driven cost increases, which are expected to continue. On a currency-adjusted basis (i.e. based on the average monthly exchange rates in 2022), Bayer expects to generate sales of 51 billion to 52 billion euros in 2023. The company anticipates EBITDA before special items of 12.5 billion to 13.0 billion on a currency-adjusted basis (Fx adj.). It forecasts core earnings per share of 7.20 to 7.40 euros (Fx adj.) and free cash flow of approximately 3.0 billion euros (Fx adj.). Net financial debt as of year-end 2023 is expected to amount to 32 billion to 33 billion euros (Fx adj.). With respect to the divisions, Bayer anticipates sales growth (Fx & portfolio adj.) of around 3 percent at Crop Science, approximately 1 percent at Pharmaceuticals, and roughly 5 percent at Consumer Health. The company also expects the EBITDA margin before special items (Fx adj.) to come in at 25 to 26 percent at Crop Science, above 29 percent at Pharmaceuticals, and around 23 percent at Consumer Health. Bayer has also prepared its guidance based on the closing exchange rates as of December 31, 2022, and the differences to the currency-adjusted forecast above are as follows: Group sales are expected to come in at 50 billion to 51 billion euros, and the Pharmaceuticals Division’s EBITDA margin before special items is projected to amount to around 30 percent. Major strides in innovation and sustainability Bayer has also made significant progress in launching and developing innovations. This is evident in the Pharmaceuticals Division, for instance, with the products Nubeqa™ and Kerendia™ as well as projects in late-stage development, such as asundexian for the prevention of stroke in atrial fibrillation patients and elinzanetant for the treatment of women in menopause. The company currently believes that these major growth drivers have a combined peak sales potential of over 12 billion euros annually. The Crop Science Division advanced the launch of new products that are designed to protect harvests even more effectively and reduce environmental impact. In the field of biologicals, it shifted its research approach to an open innovation model, with the division engaging in strategic collaborations with the Boston-based biotech company Ginkgo Bioworks and the Spanish biologicals company Kimitec, for example. Finally, the Consumer Health Division strengthened its product portfolio with the addition of Astepro™, the first steroid-free antihistamine spray on the US market that is available over the counter. It starts to work much faster, providing allergy sufferers with the relief they need. Turning to the company’s sustainability targets, Baumann explained: “In 2022, we once again managed to reduce our greenhouse gas emissions overall – while at the same time achieving dynamic growth in our businesses.” The company’s efforts are gaining ever greater recognition, he remarked, with MSCI having upgraded its environmental, social and governance (ESG) rating for Bayer from “BB” to “A”. In addition, the company has for the first time made it into the top ten in the renowned Access to Medicine index, Baumann added. The index ranks companies in terms of their related endeavors in low- and middle-income countries. Bayer is also making good progress in attaining its ambitious social responsibility goals, he said. By 2030, the company aims to help 100 million smallholder farmers in low- and middle-income countries (LMICs), satisfy the need of 100 million women in LMICs for modern contraception, and support 100 million people in underserved communities with self-care. Notes: The following tables contain the key data for the Bayer Group and its divisions for the full year and the fourth quarter of 2022. The complete Annual Report 2022 is available on the internet at: www.bayer.com/annualreport The Sustainability Report 2022 is also published on the internet at: www.bayer.com/sustainability-report The speech given by the Bayer Board of Management to the media will be available online from around 10 a.m. CET at: www.bayer.com/speeches Live broadcast of the Financial News Conference from around 10 a.m. CET and recording available from around 3 p.m. CET at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the investor conference call (from around 2 p.m. CET) and recording (from around 6 p.m. CET) available at: www.bayer.com/live-ic Print-quality photos will be available here shortly after the news conference Find more information at www.bayer.com . Follow us on twitter.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Financial Statement

08 Nov 2022

·www.worldpharmanews.com

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we were again able to boost sales and earnings," said Werner Baumann, Chairman of the Board of Management, when presenting the company's quarterly statement on Tuesday. Crop Science in particular continued its growth trajectory, and Pharmaceuticals and Consumer Health also saw sales rise against the prior-year quarter. Baumann confirmed the Group outlook for 2022. "We are right on track to achieve the full-year financial targets that we raised in August." Bayer expects the cost increases triggered by high inflation to continue next year. In Germany, the company aims to be independent of Russian gas by the end of the year. As global supply chains remain very much under strain, procurement management and supply chain stability are top priorities for Bayer. In order to shore up supply chain stability and mitigate the impact of any supply bottlenecks, the company is working closely with suppliers and contract manufacturers and is continuing to build up inventories. Third-quarter Group sales rose by 5.7 percent to 11.281 billion euros on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). Sales benefited from positive currency effects of 940 million euros (Q3 2021: 67 million euros). EBITDA before special items increased by 17.3 percent to 2.451 billion euros. This figure included a negative currency effect of 78 million euros (Q3 2021: 44 million euros). EBIT came in at 1.199 billion euros (Q3 2021: 530 million euros) after net special charges of 153 million euros (Q3 2021: 694 million euros). Net income amounted to 546 million euros (Q3 2021: 85 million euros), and core earnings per share advanced by 7.6 percent to 1.13 euros. Free cash flow declined by 11.1 percent to 1.738 billion euros. The company was able to reduce its net financial debt to 35.884 billion euros as of September 30, down 1.9 percent from June 30, 2022. Cash inflows from operating activities were partly offset by negative currency effects. New products and Eylea drive growth at Pharmaceuticals Sales of prescription medicines (Pharmaceuticals) increased by 2.9 percent (Fx & portfolio adj.) to 4.955 billion euros. Bayer continued its successful market launch of new products, especially Nubeqa and Kerendia. Sales of the cancer drug Nubeqa nearly doubled thanks to significant gains in all regions. The division also received milestone payments via its cell and gene therapy (C>) and chemoproteomics platforms. Overall sales growth was held back by tender procedures in China, particularly for the cancer drug Nexavar and the oral anticoagulant Xarelto, which saw their global sales fall by 54.0 percent and 8.1 percent (Fx & portfolio adj.), respectively. XareltoTM sales were also impacted by the expiration of its patent in Brazil. By contrast, sales of the ophthalmology drug Eylea rose by 4.3 percent (Fx & portfolio adj.). Business was up in all regions, with volumes mainly increasing in Europe and China. Sales of the long-term contraceptives in the Mirena product family grew particularly significantly, rising 20.5 percent (Fx & portfolio adj.) thanks to higher volumes and demand shifts in the United States. The divisions radiology business registered higher volumes in all regions, with sales of the Gadovist and Ultravist product lines climbing 16.6 percent and 22.1 percent (Fx & portfolio adj.), respectively. EBITDA before special items at Pharmaceuticals advanced by 15.2 percent to 1.573 billion euros. Earnings primarily benefited from the growth in sales, as well as income from the sale of non-core businesses. These positive effects more than offset ongoing investments in marketing new products as well as research and development expenses. The EBITDA margin before special items increased by 1.6 percentage points to 31.7 percent. Consumer Health grows sales and earnings Sales of self-care products (Consumer Health) advanced by 4.4 percent (Fx & portfolio adj.) to 1.548 billion euros, marking a continued strong growth trajectory across all regions against a very strong prior-year quarter. Sales in the Allergy & Cold category rose by 16.6 percent (Fx & portfolio adj.) due to continuously elevated cold incidence rates and the positive momentum behind the launch of the Astepro antihistamine nasal spray. The division also registered double-digit growth in the Dermatology category, with sales rising 14.3 percent (Fx & portfolio adj.), particularly driven by the new product Bepanthen Derma. After posting strong gains over the past two years, the Nutritionals category normalized at an elevated level with a decline of 7.9 percent (Fx & portfolio adj.). EBITDA before special items at Consumer Health climbed by 9.1 percent to 336 million euros. This was particularly due to increased sales, operational efficiencies as well as the divisions active price management. The EBITDA margin before special items declined by 1.2 percentage points to 21.7 percent as the division further invested in the launch of innovative products, especially Astepro. The margin was also impacted by inflation-related cost increases. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros.

Gene Therapy

100 Deals associated with Dexpanthenol

External Link

KEGG	Wiki	ATC	Drug Bank
D00193	Dexpanthenol	A11HA30 D03AX03 S01XA12	DB09357

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pantothenic acid deficiency	JP	TOA Eiyo Ltd.	20 Mar 1959
Vitamin B Deficiency	CN	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Foot	Phase 3	EG	Egyptian International Pharmaceutical Industries Co.	01 Jul 2011
Exanthema	Phase 3	NL	Bayer AG	01 Sep 2010
Neoplasms	Phase 3	NL	Bayer AG	01 Sep 2010
Erythema	Phase 2	FR	Bayer AG	01 Sep 2007
Skin Abnormalities	Phase 2	FR	Bayer AG	01 Aug 2007
Dry Eye Syndromes	Phase 1	MX	Laboratorios Sophia SA de CV	04 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03520348 (CTgov)	Phase 1	Dry Eye Syndromes	24	PRO-167 (PRO-167)	wqgkmxxgkf(owfiwzvkgn) = nwmaindvou ogapkkutcj (djfugbdqev, qjugesfhct - bewzcbatjz) View more	-	19 Jul 2019
				Corneregel (Corneregel®)	wqgkmxxgkf(owfiwzvkgn) = lylnpxrbll ogapkkutcj (djfugbdqev, jifeetjdhj - dfikqlnevm) View more
ARVO2009	Not Applicable	-	16	0.1% hyaluronic acid	gdupbmfikh(qmygyrwjwu) = mitlbflnbn qtjykyrfhv (xlxkfwrtoy, 13.72)	Positive	01 Apr 2009
				2% Panthenol	gdupbmfikh(qmygyrwjwu) = rloiuwowiz qtjykyrfhv (xlxkfwrtoy, 23.94)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis